In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease

Bibliographic Details
Main Authors:	Thomas Lund, Michael Tveden Gundesen, Annette Juul Vangsted, Carsten Helleberg, Einar Haukås, Trine Silkjær, Jon Thor Asmussen, Elena Manuela Teodorescu, Bo Amdi Jensen, Tobias Schmidt Slørdahl, Hareth Nahi, Anders Waage, Niels Abildgaard, Fredrik Schjesvold, Nordic Myeloma Study Group
Format:	Article
Language:	English
Published:	Nature Publishing Group 2024-04-01
Series:	Blood Cancer Journal
Online Access:	https://doi.org/10.1038/s41408-024-01046-2

Similar Items

P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.
by: Michael Gundesen, et al.
Published: (2023-08-01)

Potential value of pre-planned imaging of bone disease in multiple myeloma
by: Michael T. Gundesen, et al.
Published: (2023-07-01)

P875: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
by: Frida Bugge Askeland, et al.
Published: (2023-08-01)

P888: REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY
by: F. B. Askeland, et al.
Published: (2022-06-01)

Paired miRNA- and messenger RNA-sequencing identifies novel miRNA-mRNA interactions in multiple myeloma
by: Kristin Roseth Aass, et al.
Published: (2022-07-01)

Risk Factors and Risk Stratification of Thromboembolic Risk in Patients with Multiple Myeloma
by: Roza Chaireti, et al.
Published: (2022-08-01)

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.
by: Rasmus Sørrig, et al.
Published: (2017-01-01)

P898: A PROSPECTIVE PHASE 2 STUDY TO ASSESS MINIMAL RESIDUAL DISEASE AFTER IXAZOMIB, LENALIDOMIDE, DEXAMETHASONE (IRD) TREATMENT FOR NEWLY DIAGNOSED TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS
by: Raija Silvennoinen, et al.
Published: (2023-08-01)

Yearly zoledronic acid in postmenopausal osteoporosis.
by: Poole, K, et al.
Published: (2007)

Zoledronic Acid-Induced Insulitis in Rats
by: Heresh Rezaei, et al.
Published: (2023-06-01)

Inhibition of osteoblast activity by zoledronic acid
by: Fernanda Gonçalves Basso, et al.
Published: (2013-10-01)

Zoledronic acid sequential to teriparatide may promote greater inhibition of bone resorption than zoledronic acid alone
by: Sharon Giveon, et al.
Published: (2023-11-01)

VRD versus VCD as induction therapy before autologous stem cell transplantation in multiple myeloma: a nationwide population-based study
by: Jakob Nordberg Nørgaard, et al.
Published: (2024-04-01)

P969: VRD OUTPERFORMED VCD AS INDUCTION THERAPY BEFORE FIRST-LINE ASCT IN MULITPLE MYELOMA; RESULTS FROM A NATIONWIDE, POPULATION-BASED STUDY
by: Jakob Nordberg Nørgaard, et al.
Published: (2023-08-01)

Zoledronate prevents bone loss after stroke
by: Poole, K, et al.
Published: (2006)

Zoledronic acid in the treatment of osteoporosis: indications for use
by: Nataliya Vladimirovna Toroptsova, et al.
Published: (2011-06-01)

Identifying therapeutic biomarkers of zoledronic acid by metabolomics
by: Xiang Li, et al.
Published: (2023-04-01)

FATIGUE AND OTHER SYMPTOMS FOLLOWING INTRAVENOUS ZOLEDRONATE THERAPY
by: Warburton, S, et al.
Published: (2009)

The effects of zoledronate on iliac bone remodelling in stroke patients
by: Poole, K, et al.
Published: (2007)

Zoledronate-induced scleritis: Clinical characteristics, management, and outcomes
by: Dan He, et al.
Published: (2025-01-01)

Generic zoledronic acid for osteoporosis: focus on tolerability and safety
by: N. V. Toroptsova, et al.
Published: (2021-10-01)

Effect of mevalonate, zoledronate and BCG on monocyte/macrophage phenotype
by: A. P. Lykov, et al.
Published: (2023-06-01)

An Unknown Side Effect of Zoledronic Acid: Acute Pancreatitis
by: Ayça Demirel, et al.
Published: (2024-10-01)

Use of Zoledronic Acid in Paediatric Craniofacial Fibrous Dysplasia
by: Chiara Di Pede, et al.
Published: (2016-01-01)

Role of zoledronic acid in treatment of osteoporosis and prevention of fractures
by: A. V. Krivova, et al.
Published: (2022-01-01)

Evaluation of the tolerability of zoledronic acid preparations for parenteral administration
by: I. A. Shafieva, et al.
Published: (2022-07-01)

How zoledronic acid improves osteoporosis by acting on osteoclasts
by: Biao Wang, et al.
Published: (2022-08-01)

Effects of zoledronic acid on osteoblasts in three-dimensional culture
by: Flora Thibaut, et al.
Published: (2015-03-01)

The influence of zoledronate and teriparatide on gamma delta T cells in mice
by: Eiki Yamachika, et al.
Published: (2017-12-01)

The dynamin inhibitor, dynasore, prevents zoledronate-induced viability loss in human gingival fibroblasts by partially blocking zoledronate uptake and inhibiting endosomal acidification
by: Jacob KIRBY, et al.
Published: (2024-09-01)

P950: COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE
by: T. S. Slørdahl, et al.
Published: (2022-06-01)

Predicting the individualized risk of nonadherence to zoledronic acid among osteoporosis patients receiving the first infusion of zoledronic acid: development and validation of new predictive nomograms
by: Chong Li, et al.
Published: (2022-07-01)

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
by: Kazimierz Groen, et al.
Published: (2023-09-01)

The real‐world use and efficacy of pomalidomide for relapsed and refractory multiple myeloma in the era of CD38 antibodies
by: Agoston Gyula Szabo, et al.
Published: (2023-11-01)

The homing of prostate cancer to bone in vivo is modulated by Zoledronic acid
by: Reeves, K, et al.
Published: (2011)

Bone structure and remodelling in stroke patients: early effects of zoledronate.
by: Poole, K, et al.
Published: (2009)

Zoledronate-Induced Large Vessel Vasculitis Diagnosed by PET/CT
by: Dmitry Shchekochikhin, et al.
Published: (2023-08-01)

Polyarthritis following infusion of zoledronic acid: a case study
by: T. Campbell
Published: (2023-07-01)

Controlled delivery of zoledronate improved bone formation locally in vivo.
by: Wenlong Gou, et al.
Published: (2014-01-01)

P938: CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE CONSOLIDATION IN MYELOMA PATIENTS WITH A POSITIVE FDG PET/CT AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION: A PHASE II STUDY (CONPET)
by: J. N. Nørgaard, et al.
Published: (2022-06-01)